Executive Summary
21 federal contracts totaling $3.6B awarded or active, with 17 bullish signals dominated by health services (HHS/CMS/VA ~$1.5B), border/detention security (DHS/ICE ~$823M), and IT/engineering (GSA ~$934M), signaling sustained federal spending in preparedness, infrastructure, and cyber/IT amid long-term performance periods to 2047.
Public companies like SAIC ($447M across 2), Fluor, Northrop Grumman, and CoreCivic gain committed revenue with options upside >$1B potential. Neutral signals limited to nonprofits/low-outlay deals; risks center on firm-fixed-price overruns and funding delays, but high outlays in recent awards ($222M+ in several) indicate execution momentum.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Tracking the trend? Catch up on the prior General Federal Contracts digest from March 12, 2026.
Investment Signals (4)
- HHS/CMS Health IT & Cyber Surge (HIGH)▲
8 contracts totaling ~$1.1B for Medicare outreach, cybersecurity (Iron Vine $102M), provider screening (SparkSoft $70M), with $53M-$90M outlays signaling rapid deployment.
- DHS Border & Detention Buildout (HIGH)▲
4 contracts worth $823M including $561M border wall JV and CoreCivic $57M detention, fully obligated with 1-2.5yr execution providing near-term revenue.
- GSA IT/Engineering Longevity (MEDIUM)▲
5 awards ~$934M to SAIC ($447M total), Frontier ($268M SBIR III), Ameresco energy retrofits to 2047, with options pushing ceilings to $1.4B+.
- Options Exercise Upside >$1B (MEDIUM)▲
12 contracts hold $1B+ in unexercised options (e.g., SAIC $130M, Frontier $286M, Technical Resources $264M), exercisable through 2028-2031.
Risk Flags (3)
- Execution [HIGH RISK]▼
Firm fixed price on 12 contracts (~$2B) risks cost overruns over long periods (e.g., Caddell embassy to 2027, Ameresco to 2047).
- Market [MEDIUM RISK]▼
$0 outlays in 7 contracts worth $1.2B (e.g., border wall $561M, embassy $339M) signal potential funding delays post-2025 starts.
- Regulatory [MEDIUM RISK]▼
Time & materials/cost-plus in 6 deals (~$800M) vulnerable to audits (e.g., Fluor FEMA $134M, Porter Novelli $113M).
Opportunities (3)
- ◆
$1B+ options and extensions in health/IT (e.g., Iron Vine to 2029, SparkSoft to 2028) plus small biz designations (8(a)/HUBZone) for follow-ons.
- ◆
Energy retrofits (Ameresco $112M to 2047) and border/detention ($823M) align with federal sustainability/infrastructure priorities.
- ◆
Public cos with multiple wins: SAIC $447M GSA IT, Fluor $134M FEMA, GD $79M VA desk support offer diversified federal exposure.
Sector Themes (3)
- ◆
HHS/CMS/VA contracts ~$1.5B (42% total) emphasize cyber, Medicare tech, R&D with 50%+ outlays in recent awards.
- ◆
DHS/ICE ~$823M (23%) for border wall, detention, disaster ops signals policy-driven spend through 2028.
- ◆
13 contracts >3yrs (~70% value) to 2031-2047 provide revenue stability in engineering, energy, forestry.
Watch List (4)
- 👁
{"entity"=>"SAIC", "reason"=>"$447M across 2 GSA IT/engineering deals with $130M options to 2028", "trigger"=>"option exercises or new GSA task orders"}
- 👁
{"entity"=>"CoreCivic", "reason"=>"$57M ICE detention fully obligated, non-competed positioning for repeats", "trigger"=>"2026 renewal or outlay start"}
- 👁
{"entity"=>"Fluor Federal", "reason"=>"$134M FEMA disaster support with $102M options, $77M outlay momentum", "trigger"=>"hurricane season extensions"}
- 👁
{"entity"=>"Barnard Spencer JV", "reason"=>"$561M border wall largest award, full commitment but $0 outlay", "trigger"=>"initial funding drawdown by Q2 2026"}
Get daily alerts with 4 investment signals, 3 risk alerts, 3 opportunities and full AI analysis of all 21 filings
$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: General Federal Contracts
🇺🇸 More from United States
View all →May 27, 2026
US Pre-Market SEC Filings Roundup — May 27, 2026
US Pre-Market SEC Filings Roundup
May 27, 2026
S&P 500 Technology Sector SEC Filings — May 27, 2026
S&P 500 Technology Sector SEC Filings
May 27, 2026
Orphan Drug Approvals — May 27, 2026
Orphan Drug Approvals
May 27, 2026
Big Pharma Approvals — May 27, 2026
Big Pharma Approvals